These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

915 related items for PubMed ID: 9317195

  • 1. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
    Rodgers GP.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
    [Abstract] [Full Text] [Related]

  • 2. Pathophysiologically based drug treatment of sickle cell disease.
    Steinberg MH.
    Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
    [Abstract] [Full Text] [Related]

  • 3. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N.
    Pediatr Nurs; 2006 Oct; 32(6):541-3. PubMed ID: 17256291
    [Abstract] [Full Text] [Related]

  • 6. Established and experimental treatments for sickle cell disease.
    De Franceschi L, Corrocher R.
    Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
    [Abstract] [Full Text] [Related]

  • 7. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
    Rodgers GP, Dover GJ, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1990 Apr 12; 322(15):1037-45. PubMed ID: 1690857
    [Abstract] [Full Text] [Related]

  • 8. Sickle cell anemia: targeting the role of fetal hemoglobin in therapy.
    Coleman E, Inusa B.
    Clin Pediatr (Phila); 2007 Jun 12; 46(5):386-91. PubMed ID: 17556734
    [Abstract] [Full Text] [Related]

  • 9. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW, Kennedy LD.
    Ann Pharmacother; 1997 Nov 12; 31(11):1393-6. PubMed ID: 9391697
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A transgenic mouse model of sickle cell disorder.
    Greaves DR, Fraser P, Vidal MA, Hedges MJ, Ropers D, Luzzatto L, Grosveld F.
    Nature; 1990 Jan 11; 343(6254):183-5. PubMed ID: 2296310
    [Abstract] [Full Text] [Related]

  • 12. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1993 Jan 14; 328(2):73-80. PubMed ID: 7677965
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Pathophysiology and treatment of sickle-cell disease].
    van Beers EJ, Peters M, Biemond BJ.
    Ned Tijdschr Geneeskd; 2005 May 21; 149(21):1144-9. PubMed ID: 15940917
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sickling of nucleated erythroid precursors from patients with sickle cell anemia.
    Hasegawa S, Rodgers GP, Dwyer N, Noguchi CT, Blanchette-Mackie EJ, Uyesaka N, Schechter AN, Fibach E.
    Exp Hematol; 1998 Apr 21; 26(4):314-9. PubMed ID: 9546314
    [Abstract] [Full Text] [Related]

  • 18. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S.
    Semin Hematol; 1997 Jul 21; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.